News
APLIF
0.014
NaN%
--
Weekly Report: what happened at APLIF last week (0330-0403)?
Weekly Report · 1d ago
Appili Therapeutics Targets New Funding and Partnerships at World Vaccine Congress Washington
TipRanks · 03/30 12:23
Weekly Report: what happened at APLIF last week (0323-0327)?
Weekly Report · 03/30 10:05
Stocks in play: Appili Therapeutics Inc
Barchart · 03/30 09:55
Weekly Report: what happened at APLIF last week (0316-0320)?
Weekly Report · 03/23 10:01
Weekly Report: what happened at APLIF last week (0309-0313)?
Weekly Report · 03/16 10:01
Weekly Report: what happened at APLIF last week (0302-0306)?
Weekly Report · 03/09 10:02
Weekly Report: what happened at APLIF last week (0223-0227)?
Weekly Report · 03/02 10:01
Weekly Report: what happened at APLIF last week (0216-0220)?
Weekly Report · 02/23 10:01
Appili Therapeutics Raises C$100,000 in Second Tranche of Private Placement
TipRanks · 02/18 22:03
Stocks in play: Appili Therapeutics Inc.
Barchart · 02/18 08:56
Appili Therapeutics Announces Closing of Second Tranche of Non-Brokered Private Placement
Barchart · 02/18 06:19
Appili Therapeutics Q3 Loss Increases
NASDAQ · 02/17 04:36
Weekly Report: what happened at APLIF last week (0209-0213)?
Weekly Report · 02/16 10:01
Appili Therapeutics GAAP EPS of -$0.01
Seeking Alpha · 02/13 17:21
Appili Deepens Non-Dilutive Funding Base as Infectious Disease Pipeline Advances
TipRanks · 02/12 23:38
Weekly Report: what happened at APLIF last week (0202-0206)?
Weekly Report · 02/09 10:02
Weekly Report: what happened at APLIF last week (0126-0130)?
Weekly Report · 02/02 10:02
Weekly Report: what happened at APLIF last week (0119-0123)?
Weekly Report · 01/26 10:02
Weekly Report: what happened at APLIF last week (0112-0116)?
Weekly Report · 01/19 10:06
More
Webull provides a variety of real-time APLIF stock news. You can receive the latest news about Appili Ther through multiple platforms. This information may help you make smarter investment decisions.
About APLIF
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.